ASPI logo

ASP Isotopes Inc. Stock Price

NasdaqCM:ASPI Community·US$950.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 64 Fair Values set on narratives written by author

ASPI Share Price Performance

US$7.97
-0.79 (-9.02%)
US$7.97
-0.79 (-9.02%)
Price US$7.97

ASPI Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with low risk.

3 Risks
2 Rewards

ASP Isotopes Inc. Key Details

US$26.9m

Revenue

US$22.2m

Cost of Revenue

US$4.7m

Gross Profit

US$197.9m

Other Expenses

-US$193.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-1.53
17.62%
-717.16%
86.4%
View Full Analysis

About ASPI

Founded
2021
Employees
271
CEO
Paul Elliot Mann
WebsiteView website
aspisotopes.com

ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.

Recent ASPI News & Updates

Seeking Alpha May 28

ASP Isotopes: The Long Road From Isotopes To Income

Summary ASP Isotopes (ASPI) is rated Sell due to premature growth narrative, high capital intensity, and heavy execution risk versus current $6.89 share price. My DCF valuation implies a $2.40 fair value, reflecting the need for ASPI to prove commercial scale, margin conversion, and financing capacity. Recent business updates show segment progress—radiopharma leads revenue, Si-28 and Yb-176 shipments targeted for 2026, and Renergen Phase 1 drilling completed early. Despite $290.5M liquidity, ASPI faces negative cash flow, widening losses, and a 25% probability of failure, making current risk-reward unattractive. Read the full article on Seeking Alpha

Recent updates

No updates